ReviewBiochemical and biophysical research communications2025
Charting new frontiers in nanoparticle immunotoxicity: A perspective on current, emerging, and future approaches.
Review in Biochemical and biophysical research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Crossing the Blood-Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Review
- Enhancing the Safety of Nanoparticles in Medicine: Highlights of Progress and Critical Objectives.International journal of nanomedicine · 2026Review
- In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Advances in understanding nanoparticles' interactions with the immune system in the last two decades have shaped not only the way immunotoxicity is analyzed but also the way nanoparticles are designed for therapeutic applications. Current approaches for assessing nanoparticle immunotoxicity rely on a conventional framework established and optimized for various drug product types, including biotechnology therapeutics, small-molecule drugs, and therapeutic nucleic acids. The sophistication offered by nanotechnology drug delivery carriers is often associated with the increased complexity of the physicochemical properties of nanotechnology-based formulations and their behavior in biological systems. Such complexity often creates challenges for preclinical studies and motivates the expansion of the methodological framework to include novel approaches and optimize the existing ones. Herein, I review the experience of the Nanotechnology Characterization Laboratory in analyzing the immunotoxicity of cancer nanotechnology concepts to highlight current and emerging approaches and outline the future direction for the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.